Use of tyrosine kinase inhibitors for treating inflammatory...

Details Use of tyrosine kinase inhibitors for treating inflammatory... Use of tyrosine kinase inhibitors for treating inflammatory...

2002-06-28

2010-06-22

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S266100

Reexamination Certificate

active

07741335

ABSTRACT:
The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

REFERENCES:
patent: 3467666 (1969-09-01), Dexter et al.
patent: 3558653 (1971-01-01), Coyne et al.
patent: 3725403 (1973-04-01), Krapcho
patent: 4587342 (1986-05-01), Daluge et al.
patent: 5521184 (1996-05-01), Zimmerman
patent: 5639757 (1997-06-01), Dow et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5916769 (1999-06-01), Olsen et al.
patent: 5952374 (1999-09-01), Clarkson
patent: 6114371 (2000-09-01), Tang et al.
patent: 6133305 (2000-10-01), Tang et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6498165 (2002-12-01), Armstrong et al.
patent: 6498176 (2002-12-01), Lackey et al.
patent: 6544988 (2003-04-01), Bilodeau et al.
patent: 6762180 (2004-07-01), Roth et al.
patent: 6958335 (2005-10-01), Buchdunger et al.
patent: 2002/0010203 (2002-01-01), Lipson et al.
patent: 2002/0052386 (2002-05-01), Armistead et al.
patent: 2003/0045451 (2003-03-01), Bacus
patent: 2003/0091974 (2003-05-01), Moussy et al.
patent: 2003/0176443 (2003-09-01), Stein-Gerlach et al.
patent: 2004/0028673 (2004-02-01), Netzer et al.
patent: 2004/0110810 (2004-06-01), Ciufolini et al.
patent: 2004/0241226 (2004-12-01), Moussy et al.
patent: 2004/0242601 (2004-12-01), Moussy et al.
patent: 2004/0242612 (2004-12-01), Moussy et al.
patent: 2004/0259892 (2004-12-01), Moussy et al.
patent: 2004/0259893 (2004-12-01), Moussy et al.
patent: 2004/0266771 (2004-12-01), Moussy et al.
patent: 2004/0266797 (2004-12-01), Moussy et al.
patent: 2004/0266801 (2004-12-01), Moussy et al.
patent: 2005/0054617 (2005-03-01), Moussy et al.
patent: 2005/0059688 (2005-03-01), Moussy et al.
patent: 2005/0089838 (2005-04-01), Moussy et al.
patent: 2005/0176687 (2005-08-01), Moussy et al.
patent: 2005/0222091 (2005-10-01), Moussy et al.
patent: 2006/0166281 (2006-07-01), Moussy et al.
patent: 2006/0204459 (2006-09-01), Moussy et al.
patent: 2006/0275769 (2006-12-01), Moses et al.
patent: 198 24 922 (1999-12-01), None
patent: 198 44 003 (2000-03-01), None
patent: 0 403 238 (1990-12-01), None
patent: 0 564 409 (1993-10-01), None
patent: 0 586 020 (1994-03-01), None
patent: WO-98/18782 (1998-05-01), None
patent: WO 98 18782 (1998-05-01), None
patent: WO-9818782 (1998-05-01), None
patent: WO 98 35056 (1998-08-01), None
patent: WO 98 41525 (1998-09-01), None
patent: WO 98 50356 (1998-11-01), None
patent: WO 98 55152 (1998-12-01), None
patent: WO 99 03854 (1999-01-01), None
patent: WO-9903854 (1999-01-01), None
patent: WO 99 61028 (1999-02-01), None
patent: WO 99 11643 (1999-03-01), None
patent: WO 99 15500 (1999-04-01), None
patent: WO 99 21859 (1999-05-01), None
patent: WO 99 61422 (1999-12-01), None
patent: WO 99 65908 (1999-12-01), None
patent: WO 00 09098 (2000-02-01), None
patent: WO 00 40971 (2000-07-01), None
patent: WO 00 55139 (2000-09-01), None
patent: WO 00 56709 (2000-09-01), None
patent: WO 00 67794 (2000-11-01), None
patent: WO 00 73297 (2000-12-01), None
patent: WO 01 16130 (2001-03-01), None
patent: WO 01 27081 (2001-04-01), None
patent: WO 01 45689 (2001-06-01), None
patent: WO 01 47517 (2001-07-01), None
patent: WO 01 47950 (2001-07-01), None
patent: WO 01 49287 (2001-07-01), None
patent: 0164674 (2001-09-01), None
patent: WO 01 90104 (2001-11-01), None
patent: WO 02 40486 (2002-05-01), None
patent: WO 02 55517 (2002-07-01), None
patent: 0280925 (2002-10-01), None
patent: WO 03 002106 (2003-01-01), None
patent: WO 03 035049 (2003-05-01), None
patent: WO 03 035050 (2003-05-01), None
patent: 03062215 (2003-07-01), None
patent: 0164200 (2007-09-01), None
bbc.co.uk pp. 1-2.
Arthritis Res. 2000, 2(6):446-450.
HealingWell.com 11pages.
Areugi 1992, 41(3);428-433.
David J. Hele Respir Res 2001, 2:E003 4 pages.
Topaly et al. (Leukemia 2001) 15, 342-347.
Mohammadi Moosa et al. “Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors”, Science, vol. 276, No. 5314, 1997, pp. 955-960.
Ma, Y. et al., “Indolinone Derivatives Inhibit Constitutively Activated Kit Mutants and Kill Neoplastic Mast Cells”,Journal Of Investigative Dermatology, New York, US, vol. 114, No. 2, Feb. 2000, pp. 392-394.
Imokawa, G. “Paracrine cytokine mechanisms of epidermal hyperpigmentation in UVB-melanosis, lentigo senilis and dematofibroma,”,Pigment Cell Research, 2002, p. 34, vol. 15, Supp. 9.
James M. Grichnik, et al., “The SCF/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis,”The Journal of Investigative Dermatology, vol. III, No. 2, pp. 233-238, Aug. 1998, XP001133837.
Hachiya, A. et al., “The inhibitory effect of an extract of clove,”Journal of Investigative Dermatology, Jul. 2002, p. 341, vol. 19, No. 1.
Hattori, H. et al., “The role of the epidermal stem cell factor (SCF)/c-kit cascade in the hyperpigmentation mechanism of lentigo senilis (LS),”Pigment Cell Research, 2002, p. 58, vol. 15, Supp. 9.
A. D. Laird et al, “SU6668 Is a Potent Antiangiogenic and Antitumor Agent that Induces Regression of Established Tumors”,Cancer Research, vol. 60, pp. 4152-4160, 2000.
B. Smolich et al, “The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts”,Blood, vol. 97, No. 5, pp. 1413-1421, 2001, XP002229742.
Sinha et al., “Implications for Src Kinases in Hematopoiesis: Signal Transduction Therapeutics”,Journal of Hematotherapy&Stem Cell Research, vol. 8, pp. 465-480, 1999.
Sinha and Corey,Signal Transduction Therapeutics, pp. 471-480, 1999.
Asthma and Bone Health,NIHORBD-NRC Fact Sheets, 4 pages, Dec. 2005.
J. Lesinski, “Preventing Bone Loss”, The Connection Newspapers, pp. 1-2, May 28, 2003.
www.hopkinsmedicine.org, Bone Loss from Chemotherapy,Journal of Clinical Oncology, vol. 19(14); pp. 3306-3311, 2001.
Dolan et al., Rheumatology 41, www.rheumatology.oxfordjournals.org, pp. 1047-1051, 2002.
NIH Osteoporosis and Related Bone Diseases-National Resource Center, “What People With Inflammatory Bowel Disease Need to Know About Osteoporosis”, pp. 1-4, updated Feb. 2005.
Krystal G W, et al., “Indolonone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells”, vol. 61, No. 9, May 1, 2001, pp. 3660-3668.
Moosa, Mohammadi et al, “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors”,Science, vol. 276, No. 5314, pp. 955-960, 1997.
Defazio, et al., “Interferon β-1a downregulates TNF α-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway”,Brain research, vol. 881 (2): pp. 227-230, 2000.
J. Topaly, et al., Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells,Leukemia, vol. 15, pp. 342-347, 2001.
www.gsdl.com, “Laboratory Assessments: IBD and Allergies,” GDSL Inflammatory Bowel Disease (IBD) and Allergies, 2 pages, Dec. 2005.
www.health.ucsd.edu, “Researchers Show Beneficial Role of Bacterial DNA in Fighting Inflammatory Bowel Disease,” UCSD School of Medicine News Health Sciences Communications, 2 pages, Apr. 2002.
J. Jahnsen, et al., “Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study”, Scand. J. Gastroenterol. Feb. 2004; 39(2), abstract only.
H. Mielants, et al., “Course of gut inflammation in spondylart

Affiliated with

Also associated with

Rating

Use of tyrosine kinase inhibitors for treating inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of tyrosine kinase inhibitors for treating inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tyrosine kinase inhibitors for treating inflammatory... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4162447